Padeliporfin VTP
Upper Tract Urothelial Carcinoma (UTUC)
Phase 1/IIIActive
Key Facts
Indication
Upper Tract Urothelial Carcinoma (UTUC)
Phase
Phase 1/III
Status
Active
About ImPact Biotech
Israeli biotech leveraging VTP photodynamic therapy for minimally invasive tumor ablation across solid‑tumor indications.
View full company profileAbout ImPact Biotech
Israeli biotech leveraging VTP photodynamic therapy for minimally invasive tumor ablation across solid‑tumor indications.
View full company profileAbout ImPact Biotech
Israeli biotech leveraging VTP photodynamic therapy for minimally invasive tumor ablation across solid‑tumor indications.
View full company profileAbout ImPact Biotech
Israeli biotech leveraging VTP photodynamic therapy for minimally invasive tumor ablation across solid‑tumor indications.
View full company profileTherapeutic Areas
Other Upper Tract Urothelial Carcinoma (UTUC) Drugs
| Drug | Company | Phase |
|---|---|---|
| LiPax | LIPAC Oncology | Preclinical |
| Thulio® Laser Indication Expansion | Dornier MedTech | Clinical Validation |